Genzyme and Medtronic are out to prove that it doesn't just take time to heal a broken heart. The two companies' joint venture, MG Biotherapeutics, was created in 2004 to develop new treatments for heart attacks and other cardiovascular conditions. The company in 2006 ceased enrollment of new patients in its Phase II clinical trial, which had been testing the use of cell therapy to repair damaged heart tissue following a heart attack, after evidence showed the trial would not be successful. MG Biotherapeutics is also engaged in long-term research into next-generation cell therapies and is developing a less-invasive, catheter-based delivery system for cell therapy using Medtronic's TransAccess technology.

XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, particularly the treatment of multiple myeloma (MM) and hepatitis C. The Company’s lead compound is Recombinant Erythropoietin (rHuEPO), a known compound that it is developing for the prolongation of MM patients' survival and improvement of their quality of life. MM is a severe and incurable malignant hematological cancer of plasma cells. XTL’s second program is the Diversity Oriented Synthesis program (DOS), which is focused on the development of pre-clinical hepatitis C small molecule inhibitors, which the Company had out-licensed to Presidio Pharmaceuticals, Inc. (Presidio), which is a private specialty pharmaceutical company on March 20, 2008.

Advion develops, manufactures and globally supports mass spectrometers, novel sample introduction and assay solutions, chip- based ion sources, chromatography systems, microfluidic flow chemistry systems and consumables for life science and related industries. We seek to enhance analysis performance and workflows. Using our deep scientific and engineering knowledge of mass spectrometry and microfludics, we leverage our passionate employees’ commitment to create quality, flexible and fit-for- purpose solutions.

Diagnostic HYBRIDS was founded in 1983 by Ohio University professors and private investor and entrepreneur Dr. Wilfred Konneker. It has agreed to be acquired by Quidel for $130 million. Diagnostic HYBRIDS will tell you which kind you have. The company develops and markets cell culture kits to help identify various viruses and endocrine diseases. Its product line include kits to detect a wide range of influenza viruses, herpes simplex viruses 1 and 2, Chlamydia and Cytomegalovirus, which includes the viruses that cause chicken pox and mononucleosis. Other kits demonstrate thyroid functioning. The biotech firm also develops and sells cell-based detection products.

Qiagen N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands. Qiagen N.V. provides technologies and products for preanalytical sample preparation and linked molecular assay solutions worldwide. Its sample technologies are used to collect, stabilize, isolate, and purify deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteins from blood, bone, and tissue samples; and assay technologies are used to make specific target biomolecules, such as the DNA of a specific virus for subsequent detection and analysis. The company offers sample and assay consumable products that are used in plasmid, DNA purification; RNA purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. It also provides PCR assays, which allow PCR-based detection of viral, bacterial and parasite, human, and animal pathogens, as well as pharmacogenomic genotyping; and various other products for research in the areas of epigenetics, gene expression, micro RNA, proteomics, RNAi, and applied testing and molecular diagnostics. In addition, the company offers automated systems that provide walk-away automation of sample and assay technologies in low, medium, or high throughput scale, as well as reaction set-up and other laboratory tasks; QIAcube, which allows users in research in life sciences, applied testing, and molecular diagnostic to automate the processing of the company's consumable products; and instruments to OEM partners. Further, it provides custom services, such as whole genome amplification services, DNA sequencing, and non-cGMP DNA production on a contract basis; and sells and/or licenses technology. The company serves researchers at pharmaceutical and biotechnology companies, academic institutions, and government and private laboratories.

Novogen Limited company was founded in 1994 and is headquartered in North Ryde, Australia. Novogen Limited is engaged in pharmaceutical research and development, and marketing of consumer healthcare products. In February, 2009, the Company announced that it focuses its activities on its oncology program. The Company operates subsidiary companies in 3 geographical areas: Australia, North America and Europe. The subsidiaries are involved in the selling and marketing of Novogen's consumer healthcare products. The Company’s product range includes Phenoxodiol, Triphendiol, NV-128, and GLYC-101. The Company’s subsidiaries include Novogen Laboratories Pty Ltd, Norvogen Pty Ltd, Glycotex, Inc. and Novogen BV.

OXiGENE, Inc. company was founded in 1988 and is headquartered in Waltham, Massachusetts. OXiGENE, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, which is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase II clinical trials for other solid tumors, including non-small cell lung cancer and platinum resistant ovarian cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, which is in Phase I clinical trial for solid tumors. It has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology.

Proteome Sciences plc is a United Kingdom-based company. The Company is principally engaged in biomarker research and development primarily in the field of applied proteomics, using techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. Through its ProteoSHOP toolkit, Proteome Sciences provides proteomics solutions, including traditional two dimensional gel-based electrophoresis (2DE) and gel-free protein sequence tag technologies (PST, qPST& TMT), to pharma, biotechnology and diagnostic companies. The Company has research facilities in London, the United Kingdom and Frankfurt, Germany. Its subsidiaries include Proteome Sciences R&D Verwaltungs GmbH, Proteome Sciences R&D GmbH & Co. KG, Xzillion GmbH & Co. KG, Proteome Sciences, Inc., Veri-Q Inc., Phenomics Limited and Electrophoretics Limited.

Genzyme Pharmaceuticals, a division of leading biotech firm Genzyme, couldn't agree more. The division, at its main production facility in Liestal, Switzerland, makes chemical intermediates and active pharmaceutical ingredients used in the production of a number of drugs, many manufactured by its parent. Its main products include natural and synthetic lipids and amino acid derivatives. It has also partnered with major pharmaceutical companies to develop custom manufacturing of drugs currently in development. Additionally, Genzyme Pharmaceuticals manufactures lipid-based drug delivery systems.

Ranbaxy Laboratories Limited company is India's largest drug manufacturer, as well as a top global generics producer. Anti-infectives amoxycillin and ciprofloxacin, and cardio drug simvastatin are among Ranbaxy's top sellers; all come in several administration forms. The company also addresses gastrointestinal, musculoskeletal, and central nervous system disorders, as well as diabetes, pain, allergies, and HIV/AIDS. Its R&D focus includes new forms of existing drugs and metabolic disease treatments. The company also has a groundbreaking anti-malarial candidate in late-phase trials. Japanese drugmaker Daiichi Sankyo owns a controlling stake in Ranbaxy.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.